Cyclophosphamide Pathway, Pharmacodynamics

No Pathway Network information available for Cyclophosphamide Pathway, Pharmacodynamics

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

Disorders associated with Cyclophosphamide Pathway, Pharmacodynamics SuperPath

according to GeneCards Suite gene sharing
#DisorderTypeGenesScore
1Alcohol dependenceEnrichmentADH1B, ADH1C, ALDH27.76
2Amed syndrome, digenicEnrichmentADH5, ALDH26.00
3Alcohol sensitivity, acuteEnrichmentALDH22.99
4Cerebrooculofacioskeletal syndrome 4EnrichmentERCC12.90
5Xfe progeroid syndromeEnrichmentERCC42.90
6Kala-azar 2EnrichmentGSTP12.69
7Xeroderma pigmentosum, complementation group fEnrichmentERCC42.60
8Fanconi anemia, complementation group qEnrichmentERCC42.60
9Xeroderma pigmentosum group fEnrichmentERCC42.60
10Succinic semialdehyde dehydrogenase deficiencyEnrichmentALDH5A12.43
11Parkinson disease, mitochondrialEnrichmentADH1C2.38
12Hutchinson-gilford progeria syndromeEnrichmentERCC42.30
13KeratoconusEnrichmentALDH3A12.21
14Cockayne syndrome aEnrichmentERCC42.20
15Autosomal recessive cerebellar ataxiaEnrichmentERCC42.20
16Xeroderma pigmentosum-cockayne syndrome complexEnrichmentERCC42.20
17Cockayne syndrome bEnrichmentERCC12.13
18Cerebrooculofacioskeletal syndrome 1EnrichmentERCC12.13
19Cockayne syndromeEnrichmentERCC42.06
20Leukemia, acute lymphoblastic 3EnrichmentERCC41.95
21Xeroderma pigmentosum, variant typeEnrichmentERCC41.86
22Premature menopauseEnrichmentERCC11.79
23GliosarcomaEnrichmentMGMT1.70
24Melanoma, cutaneous malignant 1EnrichmentMGMT1.68
25Giant cell glioblastomaEnrichmentMGMT1.68
26Parkinson disease, late-onsetEnrichmentADH1C1.61
27Pancreatic cancerEnrichmentERCC41.51
28Fanconi anemia, complementation group aEnrichmentERCC41.37
29Fetal akinesia deformation sequence 1EnrichmentALDH5A11.34
30Distal arthrogryposisEnrichmentALDH5A11.29
31Spastic ataxiaEnrichmentERCC41.19
32Primary ovarian insufficiencyEnrichmentERCC11.15
33Ovarian cancerEnrichmentERCC40.92

Loading...
Loading...
Loading...